Replies to post #72 on Aldeyra Therapeutics Inc (ALDX)

[Rayn_Makr]

I agree and look forward to their progress.

I looked at the publication on PubMed: "Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement"

https://pubmed.ncbi.nlm.nih.gov/32955967/

It is free. The following COI statement is excerpted from the end of that publication. The authors affiliations with B&L and others is very encouraging. With the pipeline they should be able to partner without giving up shareholder value. I think the executive leadership is great.

Conflict of interest statement
K.J.M. has served as a consultant to Aldeyra Therapeutics, and is a co-inventor on a patent assigned to Aldeyra Therapeutics.

D.C. is an employee of and an investor in Aldeyra Therapeutics.

D.S.C. has received grants from Mallinckrodt; is a consultant for Aldeyra, Dompé, and Mallinckrodt; has received honoraria from AbbVie and Mallinckrodt; and has received travel reimbursement from AbbVie, Dompé, and Santen.

C.S.F. has received financial support from Aciont, Alcon, Aldeyra, Bausch & Lomb, Clearside, Biomedical, Dompé,, Eyegate Pharma, Mallinckrodt, Novartis, pSivida, and Santen; is an investor in Eyegate Pharma; is a consultant for Aldeyra, Allakos, Bausch & Lomb, Eyegate Pharma, Genentech, Novartis, and pSivida; and has received fees for lectures and services for speaker bureaus for Alcon, Allergan, and Mallinckrodt.

J.S. has received financial support for consultancy and research from Aldeyra, AbbVie, and Bausch & Lomb.

T.C.B. is an employee of Aldeyra Therapeutics and an investor in Novadigm Therapeutics, Springbank Pharmaceuticals, Evoke Pharma, and Aldeyra Therapeutics, and is an inventor on patents for Aldeyra Therapeutics.